# RESEARCH

**BMC Infectious Diseases** 



# Genetically defined causal effects of natural killer cells related traits in risk of infection: a Mendelian randomization study



Yingxin Lin<sup>1</sup>, Sheng Zhang<sup>1</sup>, Xueqing Wang<sup>1</sup>, Junshi Wang<sup>1</sup> and Lei Huang<sup>1\*</sup>

# Abstract

**Background** The intricate interplay between genetics and immunology often dictates the host's susceptibility to various diseases. This study explored the genetic causal relationship between natural killer (NK) cell-related traits and the risk of infection.

**Methods** Single-nucleotide polymorphisms (SNPs) significantly associated with NK cell-related traits were selected as instrumental variables to estimate their genetic causal effects on infection. SNPs from a genome-wide association study (GWAS) on NK cell-related traits, including absolute cell counts, median fluorescence intensities reflecting surface antigen levels, and relative cell counts, were used as exposure instruments. Summary-level GWAS statistics of four phenotypes of infection were used as the outcome data. The exposure and outcome data were analyzed via the two-sample Mendelian randomization method.

**Results** Each one standard deviation increase in the expression level of human leukocyte antigen (HLA)-DR on HLA-DR<sup>+</sup> NK cells was associated with a lower risk of pneumonia (P < 0.05). An increased HLA-DR<sup>+</sup> NK/CD3<sup>-</sup> lymphocyte ratio was related to a lower of risk of pneumonia (P < 0.05). Each one standard deviation increase in the absolute count of HLA-DR<sup>+</sup> NK cells was associated with a lower risk of both bacterial pneumonia and pneumonia (P < 0.05). An increased HLA-DR<sup>+</sup> NK cells was associated with a lower risk of both bacterial pneumonia and pneumonia (P < 0.05). An increased HLA-DR<sup>+</sup> NK/NK ratio was associated with a decreased risk of both pneumonia and bacterial pneumonia (P < 0.05). The results were robust under all sensitivity analyses. No evidence for heterogeneity, pleiotropy, or potential reverse causality was detected. Notably, our analysis did not reveal any significant associations between NK cell-related traits and other phenotypes of infection, including cellulitis, cystitis, and intestinal infection.

**Conclusions** HLA-DR<sup>+</sup> NK cells could be a novel immune cell trait associated with a lower risk of bacterial pneumonia or pneumonia.

**Keywords** Infection, Mendelian randomization (MR), Genome-wide association study (GWAS), Bacterial pneumonia, Pneumonia, HLA-DR<sup>+</sup> NK cell

\*Correspondence: Lei Huang hl0248@outlook.com <sup>1</sup>Department of Intensive Care, Peking University Shenzhen Hospital, Shenzhen, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicate otherwise in a credit ine to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creativecommons.org/licenses/by-nc-nd/4.0/.

# Background

Infection, which ranges from mild to life-threatening, is a persistent challenge in global health [1, 2]. The multifaceted nature of infectious agents and their continuous evolution necessitate a deeper understanding of host factors that modulate susceptibility. In addition to mere exposure, this risk is closely intertwined with the host's immune response, underscoring the need to elucidate the intricacies of our immune defenses [3].

Natural killer (NK) cells are an important type of innate immune cell and are defined as "cytotoxic innate lymphocytes with 'natural killing' capacity and antibody-dependent cell-mediated cytotoxicity" [4-6]. Unlike NK cells, whose protective effects against tumors and acute viral infections are well established in the literature [4, 7], their role against bacterial infections remains controversial. Evidence from animal models has revealed a complex and conflicting role for NK cells in the immuno-pathogenesis of bacterial infections [8, 9]. NK and NK T-Cell depletion resulted in increased bacterial burdens and increased levels of serum and splenocyte interferon-y (IFN- $\gamma$ ) in *Streptococcus pneumoniae* infection mouse model [10]. In mice infected with pulmonary non-tuberculous mycobacteria, NK cell depletion increased bacterial burden and mortality [11]. Another study revealed that NK cell deficient mice had higher survival rates and lower levels of proinflammatory cytokines than wildtype mice did [12]. On the basis of clinical evidence in humans, researchers have been unable to determine whether NK cells have a positive or negative effect on infection. A decease in the NK cells count is related an increased risk of severe infection [13], increased severity of infection [14] and a poor survival rate [15]. In addition, a lower level of IFN-y secretion by NK cells is associated with a greater risk of severe infection [13]. In contrast, an increased number of circulating NK cells was associated with early mortality in patients with severe infection [16]. Patients with severe infection due to gram-negative bacteria and septic shock suffering from multi-organ dysfunction and an increased mortality rate had elevated levels of granzyme proteins in their NK cells [17, 18]. Further research with advanced analytical techniques reveals that NK cells actually exhibit a high degree of heterogeneity [19]. This heterogeneity may explain their complex role in immune regulation [20, 21]. Thus, the role of NK cells in infection is controversial, and our understanding remains incomplete. Efforts are needed to fully elucidate and precisely define the contribution of NK cells to the development of infection.

Mendelian randomization (MR) represents a methodology for the evaluation of etiological inferences in epidemiological and genetic studies. The method employs genetic variants that are strongly correlated with exposure factors as instrumental variables, with the objective of assessing the genetic causal relationship between exposure factors and outcomes. The method exploits the random distribution of genetic factors in the human body and the fact that genetic factors are fixed at the time of fertilization to explore the genetic causal relationship between exposure factors and outcomes in a way that approximates the principles of randomized controlled trials (RCTs). This addresses the limitations of RCTs, which are currently regarded as the gold standard for determining causality. These limitations include costeffectiveness, time efficiency and ethical concerns.

By harnessing genetic variations as a tool, MR enables us to navigate the complex web of causality, offering robust insights into the relationship between NK cell populations and infection risk. We sought to test whether genetically altered NK cell-related traits were associated with infection phenotypes predominantly caused by bacteria via a two-sample summary-level MR analysis. In our study, we focused on eleven NK cell traits identified from the most recent high-quality genome-wide association study (GWAS) on immune cells. We assessed four distinct bacterial infection phenotypes: intestinal infections, pneumonia, cellulitis, and cystitis. These infection phenotypes were selected on the basis of disease diagnosis codes reported in the latest comprehensive GWAS on bacterial infections.

# Methods

## Study Design

This MR study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology - Mendelian Randomization reporting guidelines [22] (Supplementary file 1). Figure 1 provides a schematic representation of the study design. We conducted a two-sample MR analysis using publicly available summary statistics from fifteen GWASs: eleven for exposures and four for outcomes. To mitigate bias from population stratification, both exposure and outcome cohorts were restricted to individuals of European ancestry [23].

This study aimed to assess the impact of circulating NK cell immune traits on infection risk. Exposures included NK cell-related traits (described in Supplementary file 3: Table S1A; instruments detailed in Supplementary file 3: Table S2A), whereas outcomes included traits associated with intestinal infection, pneumonia, cellulitis, and cystitis (Supplementary file 3: Table S1B). All the data were sourced from publicly accessible repositories with existing ethical approval, obviating the need for additional ethical clearance.

# Data sources

Exposure: The NK cell-related traits were derived from the SardiNIA project, which was accessible via the GWAS Catalog [24] (see Supplementary file 3: Table



Fig. 1 An overview of two-sample Mendelian randomization study. Abbreviations: GWAS genome-wide association study; NK, natural killer; IV, instrument variable; MR, Mendelian randomization; IVW, inverse variance weighted; MR-PRESSO Mendelian Randomization Pleiotropy RESidual Sum and Outlier

S1A). These traits included the absolute NK count, absolute human leukocyte antigen (HLA)-DR <sup>+</sup> NK count, the ratio of NK/lymphocytes, NK/CD3<sup>-</sup> lymphocytes, HLA-DR <sup>+</sup> NK/NK, and HLA-DR<sup>+</sup> NK/CD3<sup>-</sup> lymphocytes, as well as the median fluorescence intensities of CD16<sup>-</sup>CD56<sup>+</sup> and CD45<sup>+</sup> on both NK and HLA-DR<sup>+</sup> NK cells and HLA-DR on HLA-DR<sup>+</sup> NK cells. NK cells were identified as CD16+or CD56+within the CD3-CD45+population. The HLA-DR positivity of NK cells served as an activation marker [24]. The SardiNIA study enrolled 3,757 native Sardinians without overlap [24]. Approximately 22 million single-nucleotide polymorphisms (SNPs) were imputed via a Sardinian reference panel and tested for associations, adjusting for sex, age, and age-squared [24, 25].

Outcome: Four common infection phenotypes were evaluated on the basis of disease incidence and available summary statistics from two independent European ancestry cohorts: UK Biobank [26] and FinnGen Release 9 [27] (Supplementary file 3: Table S1B). These cohorts had no overlap. The UK Biobank GWAS employed Scalable and Accurate Implementation of GEneralized mixed model (SAIGE), adjusting for relatedness, sex, birth year, and principal components [26]. The FinnGen GWAS also used SAIGE, adjusting for sex, age, principal components, and batch [27]. Phenotypes of the UK Biobank were extracted from International Classification of Diseases (ICD) billing codes derived from electronic health records, whereas phenotypes of the FinnGen population were structured according to the hierarchical subtyping system of the ICD-10 classification.

#### Instrument selection

In the primary MR analyses, SNPs were selected as instrumental variables on the basis of statistical criteria. Although the conventional *P* value threshold for instrument selection in MR studies is  $5 \times 10^{-8}$ , this approach results in an insufficient number of instruments exceeding this threshold, which leads to underpowered analyses or inflated results [28]. To obtain a minimum of five

eligible instruments, the threshold was increased by a factor of ten in a sequential manner. The final range of Pvalues employed for instrument inclusion across all traits extended from  $5 \times 10^{-8}$  to  $5 \times 10^{-6}$  in the primary analysis [29, 30]. The TwoSampleMR package identified independent variants with r<sup>2</sup><0.001 in the 1000 Genomes European ancestry data. When SNPs were not shared between exposure and outcome, we supplemented instrumental variables with proxies from the 1000G EUR dataset that met a  $r^2 > 0.8$  threshold. F statistics were calculated via the variance in exposure explained by SNPs to assess instrumental strength. The exposure variance explained  $(R^2)$  for binary traits and variable phenotype effects was calculated via the TwoSampleMR package, which used the minor allele frequency and SNP exposure effect size [31]. The F statistic followed the formula  $F = R^2(n-k-1)/2$  $(k(1-R^2))$ , where n was the sample size and k was the number of instrumental variables [32]. Only SNPs with an F statistic greater than ten were retained in the primary analyses [33, 34]. We excluded potentially weak instruments (F statistic < 10) and reduced the risk of bias [35]. Steiger filtering was performed to identify instrumental SNPs that explain more significant variation in an outcome than in an exposure, which may indicate potential reverse genetic causal relationships in subsequent MR analyses.

To complement our primary analyses and potentially improve statistical power, we conducted secondary analyses using less stringent criteria, as reported in previous literature. Specifically, we applied a *P* value threshold of  $1 \times 10^{-5}$  for SNP inclusion. Additionally, we used the linkage disequilibrium pruning criterion of  $r^2 < 0.1$  within a 500 kb window to ensure a degree of independence among the selected SNPs [24, 29, 30, 36]. This approach allowed us to balance rigorous statistical standards in our primary analyses with a more inclusive strategy in our secondary analyses, potentially capturing additional genetic signals that might contribute to the relationship between NK cell traits and infection risk.

#### **Primary MR analysis**

In our primary MR analysis, we employed a range of methods tailored to the number of instrumental SNPs. In the case of instruments comprising a single SNP, the Wald ratio was employed to derive MR effect estimates. In contrast, for instruments comprising two or more SNPs, the inverse-variance weighted (IVW) method was employed for the meta-analysis of Wald ratios, as outlined in reference [37]. For NK cell-related traits with more than three available SNPs, a variety of MR methods, including the weighted median [38], weighted mode [39], MR Egger regression [40], and Mendelian Randomization Pleiotropy RESidual Sum and Outlier (MR-PRESSO) have been employed [41]. All reported associations were presented as odds ratios (ORs) for the outcome per standard deviation increase in genetically predicted circulating immunophenotype levels. MR analyses were conducted for the outcome of GWASs from the UK Biobank and the Finn-Gen project, as well as a meta-analysis of both cohorts. Unless otherwise stated, the meta-analysis was employed as the primary outcome study.

#### Sensitivity analysis

In our study, we adhered to three fundamental assumptions to establish a genetic causal relationship: (1) the instrument must be robustly associated with the exposure; (2) it cannot influence exposure-outcome confounders; and (3) it can only affect the outcome through the risk factor. To validate these assumptions and reinforce the robustness of our findings, we conducted a series of sensitivity analyses(Fig. 1).

To ascertain whether the observed differences in instrument effect size could be attributed to pleiotropy rather than mere chance, we employed Cochran's Q test, applying a significance threshold of P < 0.05 when at least two variants were available [37]. Furthermore, we conducted leave-one-out analyses to assess the heterogeneity of our results [42]. Finally, we conducted a Steiger directionality test to validate the assumption that exposure causes outcomes [43]. The comprehensive sensitivity analyses permitted an evaluation of the robustness of our primary findings and addressed potential violations of MR assumptions.

#### Statistical analysis

All MR analyses were performed via the TwoSampleMR package (version 0.5.7) in R (version 4.2.2) [44], whereas METAL (version 2020-05-05) in Linux (version Ubuntu 22.04) was used to perform meta-analyses of the MR results [45]. We set a significance threshold of  $P_{\rm FDR} < 0.05$  after correction for the false discovery rate (FDR) on the basis of the eleven multiple tests analyzed. The MR results were considered robust if they were confirmed by at least two different methods.

# Results

#### Overview

Figure 1 provides a schematic representation of the study design. Our analysis focused on eleven NK cell-related traits selected after harmonizing the instrumental variables. All the SNPs had F statistics greater than 10, confirming their effectiveness as robust instruments (see Supplementary file 3: Tables S2A). From these, we identified four exposure-outcome pairs that showed robust genetic causal relationships (Table 1; Fig. 2). We performed separate MR analyses for the outcome GWASs from the UK Biobank and FinnGen, as well as a metaanalysis combining both cohorts. Unless otherwise

| Exposure  |   | Cellulitis                                      |                             |                        | Cystitis                                    |                                |                        | Intestinal infecti                | on             |                  | Pneumonia          |                |                         |
|---|---|---|-----------------------------|------------------------|---|--------------------------------|------------------------|-----------------------------------|----------------|------------------|--------------------|----------------|-------------------------|
|   | Number of IVs                               | OR (95% CI)                                     | <i>P</i> value              | P <sub>FDR</sub>       | OR (95% CI)                                 | <i>P</i> value                 | P <sub>FDR</sub>       | OR (95% CI)                       | <i>P</i> value | P <sub>FDR</sub> | OR (95% CI)        | <i>P</i> value | P <sub>FDR</sub>        |
| NK Absolute Count   | 15  | 0.99 (0.93, 1.05)                               | 0.733                       | 0.733                  | 1.03 (0.99, 1.08)                           | 0.13                           | 0.455                  | 1.02 (0.99, 1.06)                 | 0.167          | 0.866            | 1.01 (0.97, 1.05)  | 0.656          | 0.902                   |
| NK /lymphocyte  | 15  | 0.98 (0.96, 1.00)                               | 0.12                        | 0.44                   | 1.00 (0.98, 1.03)                           | 0.72                           | 0.799                  | 1.00 (0.98, 1.01)                 | 0.63           | 0.866            | 1.00 (0.99, 1.02)  | 0.857          | 0.943                   |
| NK /CD3- lymphocyte   | 23  | 0.99 (0.97, 1.01)                               | 0.276                       | 0.657                  | 1.01 (0.99, 1.02)                           | 0.289                          | 0.455                  | 0.99 (0.98, 1.01)                 | 0.361          | 0.866            | 1.00 (0.99, 1.01)  | 0.844          | 0.943                   |
| HLA-DR+ NK Absolute Count   | ø   | 0.96 (0.91, 1.01)                               | 0.086                       | 0.44                   | 1.02 (0.98, 1.06)                           | 0.275                          | 0.455                  | 0.99 (0.96, 1.02)                 | 0.593          | 0.866            | 0.96 (0.94, 0.99)  | 0.002          | 0.011                   |
| HLA-DR+NK/NK  | 17  | 0.97 (0.94, 1.00)                               | 0.054                       | 0.44                   | 1.00 (0.97, 1.03)                           | 0.911                          | 0.911                  | 0.99 (0.98, 1.01)                 | 0.462          | 0.866            | 0.96 (0.95, 0.98)  | < 0.001        | < 0.001                 |
| HLA-DR+NK/CD3- lymphocyte   | 15  | 0.99 (0.95, 1.03)                               | 0.555                       | 0.678                  | 1.02 (0.99, 1.05)                           | 0.257                          | 0.455                  | 1.00 (0.98, 1.02)                 | 0.891          | 0.928            | 0.97 (0.95, 0.99)  | 0.013          | 0.037                   |
| HLA-DR on HLA-DR + NK   | 17  | 0.99 (0.96, 1.01)                               | 0.366                       | 0.67                   | 1.01 (0.98, 1.03)                           | 0.596                          | 0.799                  | 1.00 (0.98, 1.02)                 | 0.928          | 0.928            | 0.98 (0.97, 0.99)  | 0.006          | 0.022                   |
| CD45 on NK  | 18  | 1.01 (0.97, 1.04)                               | 0.694                       | 0.733                  | 1.02 (1.00, 1.05)                           | 0.106                          | 0.455                  | 1.01 (0.99, 1.03)                 | 0.35           | 0.866            | 1.00 (0.98, 1.02)  | 0.975          | 0.975                   |
| CD45 on HLA-DR+NK   | 9   | 1.03 (0.95, 1.12)                               | 0.49                        | 0.674                  | 0.99 (0.92, 1.06)                           | 0.726                          | 0.799                  | 1.02 (0.98, 1.07)                 | 0.318          | 0.866            | 0.99 (0.95, 1.03)  | 0.519          | 0.902                   |
| CD16-CD56 on NK   | 20  | 1.01 (0.98, 1.04)                               | 0.459                       | 0.674                  | 0.98 (0.95, 1.00)                           | 0.103                          | 0.455                  | 1.00 (0.98, 1.02)                 | 0.919          | 0.928            | 1.00 (0.99, 1.02)  | 0.607          | 0.902                   |
| CD16-CD56 on HLA-DR + NK  | 14  | 0.98 (0.96, 1.01)                               | 0.299                       | 0.657                  | 1.02 (0.99, 1.04)                           | 0.169                          | 0.455                  | 1.00 (0.99, 1.02)                 | 0.489          | 0.866            | 1.01 (0.99, 1.03)  | 0.441          | 0.902                   |
| The results presented here were bas<br>Abbreviations: NK, natural killer; IV, i | ied on meta-analyse<br>instrument variable; | es combining data fr<br>: OR, odd ratio; Cl, co | om the UK B<br>nfidence int | iobank al<br>erval; FD | nd the FinnGen pro<br>R, false discovery ra | ject. The pri<br>ite; IVW inve | mary ana<br>rse varian | lysis employed the<br>ce weighted | VW method      | with an i        | nstrument inclusio | threshold      | of $5 \times 10^{-6}$ . |

iinhted Mendelian randomization for natural killer cell related traits by infection phenotynes Tahla 1 Drim

stated, the results reported in our study were based on meta-analyses.

### **Primary MR analysis**

To elucidate the genetic causal relationships between the immunophenotypes and infection risk, we conducted a two-sample MR analysis (Table 1; detailed results in Supplementary file 3: Table S2B, Table S2C, and Table S2D). The primary analysis utilized the IVW method with an instrument inclusion threshold of  $5 \times 10^{-6}$ .

After FDR adjustment, four significant associations between NK cell-related traits and pneumonia were identified (Fig. 2). An increased HLA-DR<sup>+</sup> NK absolute count was associated with a decreased risk of pneumonia (OR=0.96, 95% confidence interval (CI)=0.94-0.99,  $P=1.96\times10^{-3}$ ,  $P_{\rm FDR}=0.011$ ). Similarly, an elevated HLA-DR<sup>+</sup> NK/NK ratio was correlated with a reduced pneumonia risk (OR=0.96, 95% CI=0.95-0.98, P=2.01×10<sup>-6</sup>,  $P_{\rm FDR}$  <0.001). The HLA-DR<sup>+</sup> NK/CD3- lymphocyte ratio also demonstrated an inverse association with pneumonia risk (OR=0.97, 95% CI=0.95-0.98,  $P=1.34\times10^{-2}$ ,  $P_{\rm FDR}$  = 0.037). Additionally, HLA-DR expression on HLA-DR<sup>+</sup> NK cells was identified as a protective factor against pneumonia (OR=0.98, 95% CI=0.97-0.99,  $P = 5.95 \times 10^{-3}$ ,  $P_{\rm FDR} = 0.022$ ).

Furthermore, our study revealed two NK cell-related traits as protective factors specifically against bacterial pneumonia (Fig. 3). The HLA-DR<sup>+</sup> NK absolute count was inversely associated with bacterial pneumonia risk  $(OR=0.94, 95\% CI=0.91-0.97, P=6.15\times10^{-4}, P_{EDR} =$ 0.003). Similarly, an elevated HLA-DR<sup>+</sup> NK/NK ratio was associated with a reduced likelihood of bacterial pneumonia (OR=0.96, 95% CI=0.94-0.98,  $P=3.00\times10^{-4}$ ,  $P_{\rm FDR} = 0.003$ ).

To further validate the genetic causal relationships between significant NK cell-related immunophenotypes and bacterial pneumonia or pneumonia in both primary and secondary analyses, additional MR methods, including weighted mode, weighted median, and MR-PRESSO analyses were employed (Fig. 3).

Notably, our analysis did not reveal any significant associations between NK cell-related traits and other phenotypes of infections, including cellulitis, cystitis, and intestinal infection (Fig. 2; Table 1).

# Sensitivity analysis

For all four exposure-outcome pairs in primary analysis, no evidence of horizontal pleiotropy was identified (all P > 0.05). The MR Egger intercept test indicated the absence of directional pleiotropy (Table 2). The Cochran's Q test indicated the absence of significant heterogeneity (Qpval>0.05 for both the IVW and MR Egger models) (Table 2). No outliers were identified in the course of the analysis.



**Fig. 2** A heatmap of Mendelian randomization for natural killer cell related traits on the risk of infection. The MR estimates and *P* values were illustrated in the plot. The outer circle employed a color scheme to represent the direction of the estimate effect (beta), whereas the inner circle utilized a different color scheme to indicate the *P* values and *P* values with FDR correction of IVW analyses. The results were derived from a meta-analysis of data from the UK Biobank and the FinnGen project. The primary analysis employed the IVW method with an instrument inclusion threshold of  $5 \times 10^{-6}$ . Abbreviations: NK, natural killer; MR, Mendelian randomization; IVW, inverse variance weighted; MR-PRESSO Mendelian Randomization Pleiotropy RESidual Sum and Outlier; FDR, false discovery rate.

Sensitivity analyses provided further confirmation of the robustness of the observed genetic causal effects of genetic components (Table 2; Supplementary file 3: Table S2D). The stability of the results was further corroborated by scatter plots, density plots, and funnel plots (see Supplementary file 2 S1–S3). The results of the leave-one-out analyses are presented in Supplementary file 2 S4.

#### Secondary MR analysis

We also conducted a secondary analysis via the IVW method with less stringent criteria for instrumental

variable selection ( $P < 1 \times 10^{-6}$ ), revealed several associations after adjustment for FDR (detailed in Supplementary file 3: Tables S3A-3E). Our secondary analysis revealed three significant associations between NK cell-related traits and cellulitis, and one significant association with pneumonia. Specifically, an increased HLA-DR<sup>+</sup> NK absolute count was associated with a decreased risk of cellulitis (OR=0.96, 95% CI=0.93–0.98,  $P_{\rm FDR}$  = 0.012), whereas an increased HLA-DR<sup>+</sup> NK/NK ratio was also correlated with a decreased risk of cellulitis (OR=0.94–0.99,  $P_{\rm FDR}$  = 0.018). For pneumonia, the

| A Pneumonia                 |               |                    |               |         |              |
|-----------------------------|---------------|--------------------|---------------|---------|--------------|
| exposure                    | Number of IVs | OR (95% CI)        |               | P value | P value(FDR) |
| HLA-DR+ NK Absolute Count   | 8             |                    | 1             |         |              |
| Inverse variance weighted   |               | 0.96 (0.94,0.99)   | <b>⊢</b> ∎→1  | 0.002   | 0.011        |
| MR Egger                    |               | 0.93 (0.90,0.97) ⊢ |               | 0.008   |              |
| Weighted median             |               | 0.95 (0.93,0.98)   | <b>—</b>      | < 0.001 |              |
| Weighted mode               |               | 0.95 (0.93,0.97)   |               | 0.003   |              |
| MR-PRESSO                   |               | 0.96 (0.94,0.99)   | <b>⊢</b>      | 0.017   |              |
| HLA-DR+ NK/NK               | 17            |                    |               |         |              |
| Inverse variance weighted   |               | 0.96 (0.95,0.98)   | <b>⊢</b> ∎→   | < 0.001 | <0.001       |
| MR Egger                    |               | 0.96 (0.94,0.98)   | <b>⊢</b> ∎→1  | 0.007   |              |
| Weighted median             |               | 0.96 (0.94,0.98)   | <b>—</b>      | 0.001   |              |
| Weighted mode               |               | 0.95 (0.93,0.98)   | <b>—</b>      | 0.002   |              |
| MR-PRESSO                   |               | 0.96 (0.95,0.98)   | H <b>-</b>    | < 0.001 |              |
| HLA-DR+ NK /CD3- lymphocyte | 15            |                    |               |         |              |
| Inverse variance weighted   |               | 0.97 (0.95,0.99)   | <b>⊢</b> ∎−−1 | 0.013   | 0.037        |
| MR Egger                    |               | 0.95 (0.92,0.99)   |               | 0.017   |              |
| Weighted median             |               | 0.96 (0.93,0.98)   | <b></b>       | < 0.001 |              |
| Weighted mode               |               | 0.95 (0.93,0.98)   | <b>—</b>      | 0.002   |              |
| MR-PRESSO                   |               | 0.97 (0.95,0.99)   | <b>⊢</b> ∎1   | 0.027   |              |
| HLA-DR on HLA-DR+ NK        | 17            |                    |               |         |              |
| Inverse variance weighted   |               | 0.98 (0.97,0.99)   | H <b></b>     | 0.006   | 0.022        |
| MR Egger                    |               | 0.98 (0.96,1.00)   | <b>—</b>      | 0.093   |              |
| Weighted median             |               | 0.98 (0.96,1.00)   | <b></b>       | 0.119   |              |
| Weighted mode               |               | 0.98 (0.97,1.00)   |               | 0.133   |              |
| MR-PRESSO                   |               | 0.98 (0.97,0.99)   | <b>⊢</b> ∎1 ¦ | 0.014   |              |
|                             |               | 0.9                | 1             | 1.1     |              |
|                             |               |                    |               |         |              |
|                             |               |                    | Protective R  | lisk    |              |

| otective | Ris |
|----------|-----|
|          |     |

| B Bacterial pneumonia       |               |                    |               |         |              |
|-----------------------------|---------------|--------------------|---------------|---------|--------------|
| exposure                    | Number of IVs | OR (95% CI)        |               | P value | P value(FDR) |
| HLA-DR+ NK Absolute Count   | 8             |                    | 1             |         |              |
| Inverse variance weighted   |               | 0.94 (0.91,0.97)   | <b>—</b>      | 0.001   | 0.003        |
| MR Egger                    |               | 0.93 (0.87,0.98) ⊢ |               | 0.042   |              |
| Weighted median             |               | 0.94 (0.90,0.97)   | <b>—</b>      | 0.001   |              |
| Weighted mode               |               | 0.94 (0.90,0.97)   |               | 0.008   |              |
| MR-PRESSO                   |               | 0.94 (0.91,0.97)   | <b>—</b>      | 0.011   |              |
| HLA-DR+ NK/NK               | 17            |                    |               |         |              |
| Inverse variance weighted   |               | 0.96 (0.94,0.98)   | H <b>B</b> H  | < 0.001 | 0.003        |
| MR Egger                    |               | 0.95 (0.91,0.98)   | <b>—</b>      | 0.012   |              |
| Weighted median             |               | 0.95 (0.92,0.98)   |               | 0.003   |              |
| Weighted mode               |               | 0.94 (0.91,0.98)   | <b>—</b>      | 0.01    |              |
| MR-PRESSO                   |               | 0.96 (0.94,0.98)   | H <b>B</b> -1 | 0.002   |              |
| HLA-DR+ NK /CD3- lymphocyte | 15            |                    |               |         |              |
| Inverse variance weighted   |               | 0.96 (0.93,1.00)   | <b>⊢</b> ∎→1  | 0.039   | 0.111        |
| MR Egger                    |               | 0.93 (0.88,0.99)   |               | 0.042   |              |
| Weighted median             |               | 0.94 (0.90,0.97)   | <b></b>       | 0.001   |              |
| Weighted mode               |               | 0.94 (0.90,0.97)   | H-B1          | 0.003   |              |
| MR-PRESSO                   |               | 0.96 (0.93,1.00)   | <b>⊢</b> ∎→1  | 0.058   |              |
| HLA-DR on HLA-DR+ NK        | 17            |                    |               |         |              |
| Inverse variance weighted   |               | 0.98 (0.96,1.00)   | <b>⊢</b> ∎1   | 0.041   | 0.111        |
| MR Egger                    |               | 0.97 (0.95,1.00)   | <b>—</b>      | 0.064   |              |
| Weighted median             |               | 0.98 (0.96,1.01)   |               | 0.19    |              |
| Weighted mode               |               | 0.99 (0.96,1.01)   |               | 0.244   |              |
| MR-PRESSO                   |               | 0.98 (0.96,1.00)   | <b>⊢</b> ∎→ ( | 0.057   |              |
|                             |               | 0.9                | ) 1           | 1.1     |              |
|                             |               |                    | 4             | →       |              |
|                             |               |                    | Protective    | Risk    |              |

Fig. 3 A forest plot illustrating the genetic causal effect of the selected natural killer cell traits on the risk of pneumonia and bacterial pneumonia. The results were based on meta-analyses combining data from the UK Biobank and FinnGen. The primary analysis employed the IVW method with an instrument inclusion threshold of 5×10<sup>-6</sup>. Abbreviations: IV, instrument variable; OR, odds ratio; Cl, confidence interval; FDR, false discovery rate; NK, natural killer; MR, Mendelian randomization; MR-PRESSO Mendelian Randomization Pleiotropy RESidual Sum and Outlier

|                  |   | Pleiotropy          |                     |                   | Heterog        | eneity       |                 |               |              |                | Directionality              |                           |
|------------------|---|---------------------|---------------------|-------------------|----------------|--------------|-----------------|---------------|--------------|----------------|-----------------------------|---------------------------|
| Outcome          | Exposure                                      | Egger<br>intercept  | Egger se            | Egger<br>pval     | D W V          | NVI<br>Qdf   | IVW<br>Qpval    | Egger Q       | Egger<br>Qdf | Egger<br>Qpval | Correct causal<br>direction | Steiger<br>pval           |
| Pneumonia        | HLA-DR+NK Absolute Count                      | 1.00E-02            | 4.75E-03            | 0.08              | 9.86           | 7            | 0.20            | 5.42          | 9            | 0.49           | TRUE                        | 3.16E-195                 |
|                  | HLA-DR+NK/NK                                  | 1.03E-03            | 3.39E-03            | 0.77              | 12.11          | 16           | 0.74            | 12.02         | 15           | 0.68           | TRUE                        | 9.36E-249                 |
|                  | HLA-DR+NK/CD3- lymphocyte                     | 6.52E-03            | 4.37E-03            | 0.16              | 21.01          | 14           | 0.10            | 17.94         | 13           | 0.16           | TRUE                        | 3.63E-248                 |
|                  | HLA-DR on HLA-DR + NK                         | 3.11E-05            | 3.57E-03            | 0.99              | 19.54          | 16           | 0.24            | 19.54         | 15           | 0.19           | TRUE                        | 4.86E-212                 |
| Bacterial        | HLA-DR+NK Absolute Count                      | 5.10E-03            | 8.28E-03            | 0.56              | 8.49           | 7            | 0.29            | 7.98          | 9            | 0.24           | TRUE                        | 4.22E-195                 |
| pneumonia        | HLA-DR+NK/NK                                  | 4.29E-03            | 5.15E-03            | 0.42              | 15.15          | 16           | 0.51            | 14.46         | 15           | 0.49           | TRUE                        | 4.49E-249                 |
| The results pres | ented here were based on meta-analyses o      | combining data fr   | om the UK Bioban    | ık and the Finn   | Gen project.   | . The prima  | ıry analysis er | nployed the I | VW method v  | with an instru | ment inclusion thresho      | old of $5 \times 10^{-6}$ |
| Abbreviations: N | IK, natual killer; IVW, inverse variance weig | ghted; se, standard | d error; Q, Cochrar | n's Q test; pval, | P value; df, c | legree of fr | eedom           |               |              |                |                             |                           |

virl of infortion 04+ po vollid lev 4 2 Colder HLA-DR<sup>+</sup> NK/CD3 lymphocyte ratio was inversely associated with risk (OR=0.97, 95% CI=0.95-0.98,  $P_{\rm FDR}$  = 0.019), and an increased HLA-DR<sup>+</sup> NK/NK ratio was identified as a protective factor (OR=0.98, 95% CI=0.97–0.99,  $P_{\text{FDR}}$  = 0.032). Interestingly, no significant associations were found between NK cell-related traits and other infection phenotypes, including cystitis and intestinal infection, suggesting the potential specificity of the protective role of NK cells against certain types of infection.

However, it is important to note that sensitivity analyses for all four exposure-outcome pairs in this secondary analysis yielded inconsistent results, as detailed in Supplementary file 3: Table S3D.

#### Steiger directionality test

The Steiger directionality test provided further evidence to support the hypothesis that the immunophenotypes of interest were genetically causally related to bacterial pneumonia or pneumonia risk. No evidence of reverse genetic causality was identified (see Supplementary file 3: Table S2E), which reinforces the directionality of the observed associations.

### Discussion

Our comprehensive MR analysis provides compelling evidence for a genetically causal relationship between specific NK cell-related traits and the risk of pneumonia, particularly bacterial pneumonia. The primary analysis, with stringent criteria for instrumental variable selection, reveals four significant associations between NK cell-related traits and pneumonia risk. Notably, increased HLA-DR<sup>+</sup> NK absolute counts, increased HLA-DR<sup>+</sup> NK/ NK ratios, increased HLA-DR<sup>+</sup> NK/CD3<sup>-</sup> lymphocyte ratios, and increased HLA-DR expression on HLA-DR<sup>+</sup> NK cells are all associated with reduced pneumonia risk. Similarly, an elevated HLA-DR<sup>+</sup> NK/NK ratio is associated with a reduced likelihood of bacterial pneumonia. Our analysis does not reveal significant associations between NK cell-related traits and other common bacterial infection, such as cellulitis, cystitis, or intestinal infection in the primary analysis. The robustness of our findings is supported by consistent results across multiple MR methods and sensitivity analyses. The absence of significant horizontal pleiotropy and heterogeneity in most cases, along with the results of the Steiger directionality test, further strengthens the validity of our genetic causal inferences. However, the discrepancies observed in our secondary analysis with less stringent criteria highlight the importance of rigorous instrumental variable selection in MR studies. While this analysis suggests potential associations with cellulitis, the inconsistent sensitivity analysis results call for cautious interpretation.

Recent advances in the field of NK cell biology have revealed a complex landscape of heterogeneous subpopulations with diverse functional characteristics. The traditional classification methods, which are primarily based on the expression of surface markers, have identified CD56 and CD16 as the key markers for subsets of NK cells. The CD56<sup>bright</sup>CD16<sup>-</sup> and CD56<sup>dim</sup>CD16<sup>bright</sup> subsets, which collectively constitute up to 10% and at least 90% of the total NK cell population, respectively, exhibit distinct phenotypic and functional profiles. The former is predominantly associated with cytokine production, whereas the latter demonstrates potent cytotoxic activity. Further research has led to the expansion of this classification, with the identification of four additional subpopulations: the additional subpopulations identified are CD56<sup>bright</sup>CD16<sup>dim</sup>, CD56<sup>dim</sup>CD16<sup>-</sup>, CD56<sup>-</sup>CD16<sup>bright</sup>, and CD56<sup>dim</sup>CD16<sup>dim</sup> [46, 47]. This expanded classification highlights the complex heterogeneity within the NK cell population. However, the advent of sophisticated single-cell analytical techniques has further refined our understanding, revealing a landscape of NK cells that is more nuanced and complex than previously recognized. The functional diversity of NK cells is regulated by a complex interplay between inhibitory and activating receptors. Inhibitory receptors, including killer cell immunoglobulin-like receptors, CD94/NKG2A, ILT2, and TIGIT, interact with activating receptors such as NKG2D and the natural cytotoxicity receptors NKp46, NKp30, and NKp44 [48]. This intricate interplay of receptor-mediated signaling modulates NK cell responses, enabling them to exhibit natural cytotoxicity against abnormal cells, perform antibody-dependent cellular cytotoxicity, and produce various cytokines and growth factors [48, 49]. The application of advanced single-cell technologies has been pivotal in elucidating the true extent of NK cell heterogeneity. These methodologies have revealed a spectrum of NK cell states and subpopulations that were previously indiscernible, challenging traditional binary classifications and suggesting a more fluid developmental process [50]. Importantly, that the current study did not establish a genetic causal relationship between CD16<sup>-</sup>CD56<sup>+</sup> expression on NK cells and infections. This finding is in accordance with the evolving perspective on NK cell biology, which emphasizes the complexity of NK cell subsets and their functional plasticity, which extends beyond the limitations of simple surface marker-based classifications.

Although peripheral blood has been the primary source for NK cell studies owing to its accessibility, emerging evidence suggests that tissue-specific microenvironments play a crucial role in shaping NK cell phenotypes. Dogra et al. proposed a model in which the characteristics of NK cells are closely linked to their anatomical location, irrespective of age and sex [51–54]. These findings emphasize the importance of considering tissue-specific factors when studying NK cell biology and function. However, a recent study focusing on the lung, a major site of NK cell distribution, demonstrated that the proportion of NK cells in lung tissue is comparable to, or slightly greater than, that in peripheral blood [55]. This distribution differs from that observed in NK cell populations in other tissues, such as the liver and other lymphoid organs [52, 56, 57]. In light of these findings, it seems reasonable to conclude that our study's focus on peripheral blood NK cells provides a suitable proxy for the lung NK cell status, particularly in the context of pneumonia and bacterial pneumonia. This approach is likely to yield more significant results for pulmonary infections than for infections at other anatomical sites.

HLA-DR expression in NK cells was identified as a marker of cellular activation. HLA-DR<sup>+</sup> NK cells were identified as a subset associated with proliferation and activation status. In healthy humans, the proportion of HLA-DR + NK cells among all NK cells in peripheral blood and immunocompetent organs, including the spleen and liver, is typically between 0% and 37.7%. However, these cells are present in notably greater amounts in lymph nodes and adenoid [58-60]. HLA-DR<sup>+</sup> NK cells play pivotal roles in a number of different aspects of immunity. In vitro, certain cytokines, including interleukin-18, interleukin-21, interleukin-2 and interleukin-15, have been demonstrated to induce the expression of HLA-DR on NK cells [61-65]. HLA-DR<sup>+</sup> NK cells expand through interactions with dendritic cells, macrophages, and neutrophils [66–69]. NK cells can acquire MHC II (including HLA-DR) through membrane contact with dendritic cells [68, 69]. These findings suggest potential mechanisms by which the immune system can rapidly activate NK cells during infections and orchestrate a coordinated defense against infections. Similarly, HLA-DR<sup>+</sup> NK cells have been linked to elevated IFN-y production, as observed in CD16<sup>-</sup>CD56<sup>+</sup> NK cells [60, 62, 64, 69]. Furthermore, IFN- $\gamma$  has been demonstrated to induce high HLA-DR expression in NK cells. Furthermore, HLA-DR<sup>+</sup> CD11c<sup>+</sup> NK cells appear to be capable of ingesting and subsequently presenting particular antigens to CD4<sup>+</sup> and CD8<sup>+</sup> CD11c<sup>+</sup> T cells, thereby triggering their activation and proliferation [59, 70, 71]. This finding suggests potential involvement in antigen presentation, acting as a conduit between innate and adaptive immunity. An elevated level of circulating HLA-DR<sup>+</sup> NK cells has been observed in certain pathological conditions, including viral and bacterial infections [70, 72–76]. A high proportion of circulating HLA-DR<sup>+</sup> cells are detected in patients infected with human immunodeficiency virus, hepatitis C virus, human cytomegalovirus and dengue virus [66, 71, 73, 77-79]. These cells were found to play a protective role in the immune response, demonstrating a correlation with the first line of defense, IFN- $\gamma$  production, cytotoxicity and antigen presentation. It is hypothesized that enhancing the activity of HLA-DR<sup>+</sup> NK cells could result in more favorable outcomes in cases of viral and bacterial infections. It is further postulated that a genetic predisposition to generate a greater proportion of HLA-DR<sup>+</sup> NK cells in response to infections could confer enhanced protection against bacterial pneumonia or pneumonia.

The present study was characterized by several strengths and weaknesses. To guarantee the dependability of our study, we implemented a series of comprehensive measures, including enrollment in the most recently published, high-quality GWAS on the immunecell spectrum. The other GWAS database on NK cells, which includes 46 subtypes, was not included in the present study since it only included females and the sample size was relatively small. Notably, in addition to the limitations of the MR methodology, which was previously reviewed [80], this study was also subject to several other limitations. (1) MR analysis based on populations of European ancestry would limit the generalizability of the findings. (2) The discrepancies observed in our secondary analysis with less stringent criteria highlighted the importance of rigorous instrumental variable selection in MR studies. Although this analysis indicated the possibility of an association with cellulitis, the inconsistent results of the sensitivity analysis precluded a definitive interpretation. (3) The utilization of the ICD for diagnosis enhances diagnostic accuracy, which might lead to several notable limitations. It was possible that milder infection or those managed in outpatient settings without a formal diagnosis might be underrepresented in the dataset. The study did not differentiate between infection on the basis of their causative agents, which precluded analysis of potential variations in NK cell responses to different pathogens. The observation that each subject in the study experienced only a few infections throughout their lifetime suggested that our dataset predominantly captured severe infections or instances of multiple infections. It was important to consider these limitations when attempting to generalize the findings to broader infectious disease contexts. (4) Transient factors, including age and lifestyle, might influence the NK cell-related traits captured at a particular moment. It was therefore possible that these factors did not accurately represent the lifelong immune properties dictated by the gene in question. Further investigations using large clinical cohorts are needed to elucidate the precise roles and mechanisms of NK cells during the onset and progression of certain infections. Such insights could inform the development of NK cell-based immunotherapies for specific patients. It would be advantageous for future studies to adopt a combined approach, integrating genetic, immunological and pharmacological perspectives, to gain a deeper understanding of the dualistic functions of NK cells in the context of infection pathogenesis.

## Conclusions

In conclusion, our findings revealed a negative correlation between a high absolute HLA-DR<sup>+</sup> NK count and the risk of developing bacterial pneumonia and all types of pneumonia. Moreover, the ratio of HLA-DR<sup>+</sup> NK to CD3<sup>-</sup> lymphocytes was identified as a factor associated with a reduced risk of bacterial pneumonia and all forms of pneumonia. These findings constitute a novel discovery in the field of research. While the intricate roles of NK cells in infections continue to unfold, this study has shed light on specific HLA-DR<sup>+</sup> NK cell subsets that might be crucial in determining the risk of infection.

# Abbreviations

| NK        | Natural killer  |
|-----------|---|
| IFN-γ     | Interferon-y  |
| MR        | Mendelian randomization                                   |
| RCT       | Randomized controlled trial                               |
| GWAS      | Genome-wide association study                             |
| HLA       | Human leukocyte antigen                                   |
| SNP       | Singlesingle-nucleotide polymorphism                      |
| SAIGE     | Scalable and Accurate Implementation of GEneralized mixed |
|           | model   |
| ICD       | International Classification of Diseases                  |
| IVW       | Inverseinverse-variance weighted                          |
| MR-PRESSO | Mendelian Randomization Pleiotropy RESidual Sum and       |
|           | Outlier   |
| OR        | Odds ratio  |
| FDR       | False discovery rate                                      |
| CI        | Confidence interval                                       |

#### Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s12879-024-09890-0.

| Supplementary Material 1 |  |
|--------------------------|--|
| Supplementary Material 2 |  |
| Supplementary Material 3 |  |

#### Acknowledgements

We acknowledge the UK Biobank, FinnGen, and Sardinia project participants and investigators. We also acknowledge the Medical Research Council Integrative Epidemiology Unit (MRC-IEU, University of Bristol, UK).

#### Author contributions

All authors have approved the submitted final version and are to be personally accountable for their contributions. YXL wrote the paper taking into account all the coauthors' comments and suggestions and was responsible for the final content, conducting the literature search, and analyzing the data. SZ, XQW, and JSW advised on the analyses and drafted the paper. LH designed the study, advised on the analyses and visualization, and supervised the study. All authors revised the paper, interpreted the results, and read and approved the final manuscripts.

#### Funding

This work was supported by Shenzhen High-level Hospital Construction Fund, Peking University Shenzhen Hospital Scientific Research Fund (KYQD2023301 and LCYJ2022008) and Scientific Research Funding of Shenzhen Society of Health Economics (No. 202422). The funder had no role in the study design, data collection, data analysis, data interpretation, writing of the report, or decision to submit the article for publication.

#### Data availability

No datasets were generated or analysed during the current study.

#### Declarations

#### Ethics approval and consent to participate

Not applicable. Only publicly available summary statistics were used.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare no competing interests.

Received: 19 November 2023 / Accepted: 5 September 2024 Published online: 17 September 2024

#### References

- GBD 2017 Causes of Death Collaborators. Global, regional, and national agesex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the global burden of Disease Study 2017. Lancet Lond Engl. 2018;392(10159):1736–88.
- GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the global burden of Disease Study 2016. Lancet Lond Engl. 2017;390(10100):1151–210.
- Russell JA, Meyer NJ, Walley KR. Use of mendelian randomization to better understand and treat sepsis. Intensive Care Med. 2022;48(11):1638–41.
- Orange JS. Natural killer cell deficiency. J Allergy Clin Immunol. 2013;132(3):515–25.
- 5. Ma L, Li Q, Cai S, Peng H, Huyan T, Yang H. The role of NK cells in fighting the virus infection and sepsis. Int J Med Sci. 2021;18(14):3236–48.
- Cerwenka A, Lanier LL. Natural killer cell memory in infection, inflammation and cancer. Nat Rev Immunol. 2016;16(2):112–23.
- Hesker PR, Krupnick AS. The role of natural killer cells in pulmonary immunosurveillance. Front Biosci Sch Ed. 2013;5(2):575–87.
- Horowitz A, Stegmann KA, Riley EM. Activation of natural killer cells during microbial infections. Front Immunol. 2011;2:88.
- Clark SE, Filak HC, Guthrie BS, Schmidt RL, Jamieson A, Merkel P, et al. Bacterial manipulation of NK Cell Regulatory Activity increases susceptibility to Listeria monocytogenes infection. PLoS Pathog. 2016;12(6):e1005708.
- Christaki E, Diza E, Giamarellos-Bourboulis EJ, Papadopoulou N, Pistiki A, Droggiti DI, et al. NK and NKT Cell Depletion alters the outcome of experimental pneumococcal pneumonia: relationship with regulation of Interferon-y production. J Immunol Res. 2015;2015:532717.
- Lai HC, Chang CJ, Lin CS, Wu TR, Hsu YJ, Wu TS et al. NK Cell-Derived IFN-γ Protects against Nontuberculous Mycobacterial Lung Infection. J Immunol Baltim Md. 1950. 2018;201(5):1478–90.
- Guo Y, Luan L, Patil NK, Wang J, Bohannon JK, Rabacal W, et al. IL-15 enables septic shock by maintaining NK Cell Integrity and function. J Immunol Baltim Md 1950. 2017;198(3):1320–33.
- Forel JM, Chiche L, Thomas G, Mancini J, Farnarier C, Cognet C, et al. Phenotype and functions of natural killer cells in critically-ill septic patients. PLoS ONE. 2012;7(12):e50446.
- Gogos C, Kotsaki A, Pelekanou A, Giannikopoulos G, Vaki I, Maravitsa P, et al. Early alterations of the innate and adaptive immune statuses in sepsis according to the type of underlying infection. Crit Care Lond Engl. 2010;14(3):R96.
- Giamarellos-Bourboulis EJ, Tsaganos T, Spyridaki E, Mouktaroudi M, Plachouras D, Vaki I, et al. Early changes of CD4-positive lymphocytes and NK cells in patients with severe Gram-negative sepsis. Crit Care Lond Engl. 2006;10(6):R166.
- Andaluz-Ojeda D, Iglesias V, Bobillo F, Almansa R, Rico L, Gandía F, et al. Early natural killer cell counts in blood predict mortality in severe sepsis. Crit Care Lond Engl. 2011;15(5):R243.

- Rucevic M, Fast LD, Jay GD, Trespalcios FM, Sucov A, Siryaporn E, et al. Altered levels and molecular forms of granzyme k in plasma from septic patients. Shock Augusta Ga. 2007;27(5):488–93.
- Lauw FN, Simpson AJ, Hack CE, Prins JM, Wolbink AM, van Deventer SJ, et al. Soluble granzymes are released during human endotoxemia and in patients with severe infection due to gram-negative bacteria. J Infect Dis. 2000;182(1):206–13.
- Horowitz A, Strauss-Albee DM, Leipold M, Kubo J, Nemat-Gorgani N, Dogan OC, et al. Genetic and environmental determinants of human NK cell diversity revealed by mass cytometry. Sci Transl Med. 2013;5(208):208ra145.
- Vallejo J, Cochain C, Zernecke A, Ley K. Heterogeneity of immune cells in human atherosclerosis revealed by scRNA-Seq. Cardiovasc Res. 2021;117(13):2537–43.
- Rosati E, Rios Martini G, Pogorelyy MV, Minervina AA, Degenhardt F, Wendorff M, et al. A novel unconventional T cell population enriched in Crohn's disease. Gut. 2022;71(11):2194–204.
- 22. Skrivankova VW, Richmond RC, Woolf BAR, Davies NM, Swanson SA, VanderWeele TJ, et al. Strengthening the reporting of observational studies in epidemiology using mendelian randomisation (STROBE-MR): explanation and elaboration. BMJ. 2021;375:n2233.
- Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al. Mendelian randomization. Nat Rev Methods Primer. 2022;2:6.
- 24. Orrù V, Steri M, Sidore C, Marongiu M, Serra V, Olla S, et al. Complex genetic signatures in immune cells underlie autoimmunity and inform therapy. Nat Genet. 2020;52(10):1036–45.
- Sidore C, Busonero F, Maschio A, Porcu E, Naitza S, Zoledziewska M, et al. Genome sequencing elucidates sardinian genetic architecture and augments association analyses for lipid and blood inflammatory markers. Nat Genet. 2015;47(11):1272–81.
- 26. Gagliano Taliun SA, VandeHaar P, Boughton AP, Welch RP, Taliun D, Schmidt EM, et al. Exploring and visualizing large-scale genetic associations by using PheWeb. Nat Genet. 2020;52(6):550–2.
- 27. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. Finn-Gen provides genetic insights from a well-phenotyped isolated population. Nature. 2023;613(7944):508–18.
- Boddy S, Islam M, Moll T, Kurz J, Burrows D, McGown A, et al. Unbiased metabolome screen leads to personalized medicine strategy for amyotrophic lateral sclerosis. Brain Commun. 2022;4(2):fcac069.
- Julian TH, Cooper-Knock J, MacGregor S, Guo H, Aslam T, Sanderson E, et al. Phenome-wide mendelian randomisation analysis identifies causal factors for age-related macular degeneration. eLife. 2023;12:e82546.
- Sanna S, van Zuydam NR, Mahajan A, Kurilshikov A, Vich Vila A, Võsa U, et al. Causal relationships among the gut microbiome, short-chain fatty acids and metabolic diseases. Nat Genet. 2019;51(4):600–5.
- Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880–906.
- Shim H, Chasman DI, Smith JD, Mora S, Ridker PM, Nickerson DA, et al. A multivariate genome-wide association analysis of 10 LDL subfractions, and their response to statin treatment, in 1868 caucasians. PLoS ONE. 2015;10(4):e0120758.
- Davies NM, Holmes MV, Davey Smith G. Reading mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ. 2018;362:k601.
- Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658–65.
- Burgess S, Thompson SG, CRP CHD Genetics Collaboration. Avoiding bias from weak instruments in mendelian randomization studies. Int J Epidemiol. 2011;40(3):755–64.
- Wang C, Zhu D, Zhang D, Zuo X, Yao L, Liu T, et al. Causal role of immune cells in schizophrenia: mendelian randomization (MR) study. BMC Psychiatry. 2023;23(1):590.
- Bowden J, Del Greco MF, Minelli C, Davey Smith G, Sheehan N, Thompson J. A framework for the investigation of pleiotropy in two-sample summary data mendelian randomization. Stat Med. 2017;36(11):1783–802.
- Bowden J, Davey Smith G, Haycock PC, Burgess S. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304–14.
- Hartwig FP, Davey Smith G, Bowden J. Robust inference in summary data mendelian randomization via the zero modal pleiotropy assumption. Int J Epidemiol. 2017;46(6):1985–98.

- Verbanck M, Chen CY, Neale B, Do R. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693–8.
- Corbin LJ, Richmond RC, Wade KH, Burgess S, Bowden J, Smith GD, et al. BMI as a modifiable risk factor for type 2 diabetes: refining and understanding causal estimates using mendelian randomization. Diabetes. 2016;65(10):3002–7.
- Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.
- Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, et al. The MR-Base platform supports systematic causal inference across the human phenome. eLife. 2018;7:e34408.
- Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinforma Oxf Engl. 2010;26(17):2190–1.
- Zimmer J. CD56dimCD16dim Natural Killer (NK) cells: the Forgotten Population. HemaSphere. 2020;4(2):e348.
- Amand M, Iserentant G, Poli A, Sleiman M, Fievez V, Sanchez IP, et al. Human CD56dimCD16dim cells as an Individualized Natural Killer Cell Subset. Front Immunol. 2017;8:699.
- 48. Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56.
- 49. Caligiuri MA. Human natural killer cells. Blood. 2008;112(3):461–9.
- Rebuffet L, Melsen JE, Escalière B, Basurto-Lozada D, Bhandoola A, Björkström NK, et al. High-dimensional single-cell analysis of human natural killer cell heterogeneity. Nat Immunol. 2024;25(8):1474–88.
- 51. Theresine M, Patil ND, Zimmer J. Airway Natural Killer Cells and Bacteria in Health and Disease. Front Immunol. 2020;11:585048.
- Björkström NK, Ljunggren HG, Michaëlsson J. Emerging insights into natural killer cells in human peripheral tissues. Nat Rev Immunol. 2016;16(5):310–20.
- Dogra P, Rancan C, Ma W, Toth M, Senda T, Carpenter DJ, et al. Tissue determinants of human NK Cell Development, function, and Residence. Cell. 2020;180(4):749–e76313.
- 54. Freud AG, Mundy-Bosse BL, Yu J, Caligiuri MA. The Broad Spectrum of Human Natural Killer Cell Diversity. Immunity. 2017;47(5):820–33.
- Marquardt N, Kekäläinen E, Chen P, Kvedaraite E, Wilson JN, Ivarsson MA, et al. Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69-CD56dim cells. J Allergy Clin Immunol. 2017;139(4):1321–e13304.
- Marquardt N, Béziat V, Nyström S, Hengst J, Ivarsson MA, Kekäläinen E, et al. Cutting edge: identification and characterization of human intrahepatic CD49a + NK cells. J Immunol Baltim Md 1950. 2015;194(6):2467–71.
- Sharkey AM, Xiong S, Kennedy PR, Gardner L, Farrell LE, Chazara O et al. Tissue-Specific Education of Decidual NK Cells. J Immunol Baltim Md. 1950. 2015;195(7):3026–32.
- Mizrahi S, Yefenof E, Gross M, Attal P, Ben Yaakov A, Goldman-Wohl D, et al. A phenotypic and functional characterization of NK cells in adenoids. J Leukoc Biol. 2007;82(5):1095–105.
- Burt BM, Plitas G, Nguyen HM, Stableford JA, Bamboat ZM, Dematteo RP. Circulating HLA-DR(+) natural killer cells have potent lytic ability and weak antigen-presenting cell function. Hum Immunol. 2008;69(8):469–74.
- Erokhina SA, Streltsova MA, Kanevskiy LM, Grechikhina MV, Sapozhnikov AM, Kovalenko EI. HLA-DR-expressing NK cells: effective killers suspected for antigen presentation. J Leukoc Biol. 2021;109(2):327–37.
- 61. Senju H, Kumagai A, Nakamura Y, Yamaguchi H, Nakatomi K, Fukami S, et al. Effect of IL-18 on the expansion and phenotype of human natural killer cells: application to Cancer Immunotherapy. Int J Biol Sci. 2018;14(3):331–40.
- 62. Evans JH, Horowitz A, Mehrabi M, Wise EL, Pease JE, Riley EM, et al. A distinct subset of human NK cells expressing HLA-DR expand in response to IL-2 and can aid immune responses to BCG. Eur J Immunol. 2011;41(7):1924–33.
- Loyon R, Picard E, Mauvais O, Queiroz L, Mougey V, Pallandre JR, et al. IL-21-Induced MHC class II + NK cells promote the expansion of human uncommitted CD4 + Central Memory T Cells in a Macrophage Migration Inhibitory factor-dependent manner. J Immunol Baltim Md 1950. 2016;197(1):85–96.

- Erokhina SA, Streltsova MA, Kanevskiy LM, Telford WG, Sapozhnikov AM, Kovalenko El. HLA-DR + NK cells are mostly characterized by less mature phenotype and high functional activity. Immunol Cell Biol. 2018;96(2):212–28.
- 65. Vukicevic M, Chalandon Y, Helg C, Matthes T, Dantin C, Huard B, et al. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells. Eur J Immunol. 2010;40(11):3246–54.
- Rölle A, Halenius A, Ewen EM, Cerwenka A, Hengel H, Momburg F. CD2-CD58 interactions are pivotal for the activation and function of adaptive natural killer cells in human cytomegalovirus infection. Eur J Immunol. 2016;46(10):2420–5.
- Rabinowich H, Pricop L, Herberman RB, Whiteside TL. Expression and function of CD7 molecule on human natural killer cells. J Immunol Baltim Md 1950. 1994;152(2):517–26.
- Benlahrech A, Donaghy H, Rozis G, Goodier M, Klavinskis L, Gotch F, et al. Human NK Cell Up-regulation of CD69, HLA-DR, Interferon γ Secretion and cytotoxic activity by Plasmacytoid Dendritic Cells is regulated through overlapping but different pathways. Sensors. 2009;9(1):386–403.
- Langers I, Renoux V, Reschner A, Touzé A, Coursaget P, Boniver J, et al. Natural killer and dendritic cells collaborate in the immune response induced by the vaccine against uterine cervical cancer. Eur J Immunol. 2014;44(12):3585–95.
- Voynova EN, Skinner J, Bolland S. Expansion of an atypical NK cell subset in mouse models of systemic lupus erythematosus. J Immunol Baltim Md 1950. 2015;194(4):1503–13.
- Costa-García M, Ataya M, Moraru M, Vilches C, López-Botet M, Muntasell A. Human cytomegalovirus Antigen Presentation by HLA-DR+NKG2C+adaptive NK cells specifically activates Polyfunctional Effector Memory CD4+T lymphocytes. Front Immunol. 2019;10:687.
- Pokkali S, Das SD, Selvaraj A. Differential upregulation of chemokine receptors on CD56 NK cells and their transmigration to the site of infection in tuberculous pleurisy. FEMS Immunol Med Microbiol. 2009;55(3):352–60.
- Naluyima P, Eller MA, Laeyendecker O, Quinn TC, Serwadda D, Sewankambo NK, et al. Impaired natural killer cell responses are associated with loss of the highly activated NKG2A(+)CD57(+)CD56(dim) subset in HIV-1 subtype D infection in Uganda. AIDS Lond Engl. 2014;28(9):1273–8.
- Luo Z, Li Z, Martin L, Hu Z, Wu H, Wan Z, et al. Increased natural killer cell activation in HIV-Infected immunologic non-responders correlates with CD4 +T cell recovery after antiretroviral therapy and viral suppression. PLoS ONE. 2017;12(1):e0167640.
- Lichtfuss GF, Cheng WJ, Farsakoglu Y, Paukovics G, Rajasuriar R, Velayudham P, et al. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation. J Immunol Baltim Md 1950. 2012;189(3):1491–9.
- Schierloh P, Yokobori N, Alemán M, Musella RM, Beigier-Bompadre M, Saab MA, et al. Increased susceptibility to apoptosis of CD56dimCD16 + NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J Immunol Baltim Md 1950. 2005;175(10):6852–60.
- Azeredo EL, De Oliveira-Pinto LM, Zagne SM, Cerqueira DIS, Nogueira RMR, Kubelka CF. NK cells, displaying early activation, cytotoxicity and adhesion molecules, are associated with mild dengue disease. Clin Exp Immunol. 2006;143(2):345–56.
- Marras F, Nicco E, Bozzano F, Di Biagio A, Dentone C, Pontali E, et al. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc Natl Acad Sci U S A. 2013;110(29):11970–5.
- Serti E, Chepa-Lotrea X, Kim YJ, Keane M, Fryzek N, Liang TJ, et al. Successful Interferon-Free Therapy of Chronic Hepatitis C virus infection normalizes natural killer cell function. Gastroenterology. 2015;149(1):190–e2002.
- Davey Smith G, Hemani G. Mendelian randomization: genetic anchors for causal inference in epidemiological studies. Hum Mol Genet. 2014;23(R1):R89–98.

# **Publisher's note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.